Login
$CYTK
$52.61 -$0.56 (1.05%) After hours

$CYTK 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027

28 Aug 2026 8-K: Other Events

Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

13 Aug 2026 8-K: Other Events

On August 13, 2026, Cytokinetics, Incorporated (the “Company”) filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory ...

06 Aug 2026 8-K: Results of Operations and Financial Condition

Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC;

27 May 2026 8-K: Submission of Matters to a Vote of Security Holders

The following is a brief description of each matter voted upon at the Company’s Annual Meeting of Stockholders on May 27, 2026 (the “Annual Meeting”), as well as the number of votes cast for or against each matter and the number of abste...

08 May 2026 8-K: Other Events

Cytokinetics, Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwr...

05 May 2026 8-K: Other Events

Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-lo...

05 May 2026 8-K: Results of Operations and Financial Condition

U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand;

24 Feb 2026 8-K: Results of Operations and Financial Condition

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe;

17 Feb 2026 8-K: Other Events

Cytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive...

19 Dec 2025 8-K: Other Events

On December 19, 2025, Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration ("FDA") has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive ...

12 Dec 2025 8-K: Other Events

On December 12, 2025, Cytokinetics, Incorporated ("Cytokinetics" or the "Company") announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing a...

14 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

On November 13, 2025, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Jeffrey J. Hessekiel, pursuant to which Mr. Hessekiel has agreed to serve as the Company’s Executive Vice ...

05 Nov 2025 8-K: Results of Operations and Financial Condition

Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track

22 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE, dated as of September 19, 2025, between Cytokinetics, Incorporated, a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).

16 Sep 2025 8-K: Other Events

On September 15, 2025, Cytokinetics, Incorporated (the “Company”) participated in a Late Cycle Meeting with the United States Food and Drug Administration (“FDA”) in connection with the Company’s New Drug Application (“NDA”) for aficamte...

03 Sep 2025 8-K: Other Events

Improves Cardiac Structure and Function Compared to Metoprolol;

02 Sep 2025 8-K: Other Events

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol

20 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

On August 19, 2025, (the “Effective Date”), the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, James M. Daly to f...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China;

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support